Viewing Study NCT00562068

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:43 PM
Ignite Modification Date: 2026-03-06 @ 6:53 AM
Study NCT ID: NCT00562068
Status: UNKNOWN
Last Update Posted: 2013-08-26
First Post: 2007-11-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
Sponsor: Cancer Research UK
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma View
None Small Intestine Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None recurrent adult T-cell leukemia/lymphoma View
None stage I adult T-cell leukemia/lymphoma View
None stage II adult T-cell leukemia/lymphoma View
None stage III adult T-cell leukemia/lymphoma View
None stage IV adult T-cell leukemia/lymphoma View
None anaplastic large cell lymphoma View
None angioimmunoblastic T-cell lymphoma View
None small intestine lymphoma View
None peripheral T-cell lymphoma View